Global Cancer Monoclonal Antibodies Market Report 2021 - Trends, Share, Size, Growth, Opportunity and Forecast to 2026 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cancer Monoclonal Antibodies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

The global cancer monoclonal antibodies market exhibited moderate growth during 2015-2020. Looking forward, the publisher expects the global cancer monoclonal antibodies market to grow at a CAGR of 4.19% during 2021-2026.

The increasing prevalence of cancer across the globe is one of the key factors driving the growth of the market. In comparison to traditionally used non-targeted therapies, such as chemotherapy, monoclonal antibodies have reduced side-effects on the patient's body and can also be used for the treatment of autoimmune and inflammatory diseases.

Furthermore, widespread adoption of cost-efficient biosimilar monoclonal antibodies by medical practitioners and oncologists is also providing a boost to the market growth. With technological advancements in gene sequencing and target gene selection, these antibodies can be modified to have similar properties to that of a pharmaceutical drug.

They have the same efficiency but are available at reduced prices than the original medicine, which aids in enhancing the cost-efficiency of the treatment, thereby contributing to the increasing demand for the product across the globe.

Other factors, including rising preference for personalized medicines, extensive research and development (R&D) activities and significant improvements in the healthcare infrastructure, are projected to drive the market further.

Key Questions Answered in This Report:

• How has the global cancer monoclonal antibodies market performed so far and how will it perform in the coming years?
• What are the key regional markets?
• What has been the impact of COVID-19 on the global cancer monoclonal antibodies market?
• What is the breakup of the market based on the antibody type?
• What is the breakup of the market based on the medication type?
• What is the breakup of the market based on the application?
• What is the breakup of the market based on the end-user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global cancer monoclonal antibodies market and who are the key players?
• What is the degree of competition in the industry?

Companies Mentioned

• AbbVie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly
• Company
• Genmab A/S
• GlaxoSmithKline Plc.
• Johnson & Johnson
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Roche Holding AG
• Seattle Genetics Inc.
• Spectrum Pharmaceuticals Inc.

Breakup by Antibody Type:

• Murine Antibodies
• Chimeric Antibodies
• Humanized Antibodies
• Others

Breakup by Medication Type:

• Bevacizumab (Avastin)
• Rituximab (Rituxan)
• Trastuzumab (Herceptin)
• Cetuximab (Erbitux)
• Panitumumab (Vectibix)
• Others

Breakup by Application:

• Breast Cancer
• Blood Cancer
• Liver Cancer
• Brain Cancer
• Colorectal Cancer
• Others

Breakup by End-User:

• Hospitals and Clinics
• Pharmacies
• Research Laboratories
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Latin America
• Brazil
• Mexico
• Middle East and Africa

For more information about this report visit https://www.researchandmarkets.com/r/psqae6